# Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS

> **NCT02017912** · PHASE2 · COMPLETED · sponsor: **Brainstorm-Cell Therapeutics** · enrollment: 48 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **BIOLOGICAL:** Nurown MSC-NTF cells
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02017912
- **Lead sponsor:** Brainstorm-Cell Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2016-03
- **Final completion:** 2016-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02017912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02017912, "Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02017912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*